SuperworthOlema Pharmaceuticals OLMA
- Market cap
- $560.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Olema Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $19.5M+10% | $25.9M+20% | $29.9M+31% | $29.1M+62% | $33.2M+71% | $32.3M+25% | $30.6M+3% | $43.9M+51% | $40M+20% | $43.2M+34% | $49.2M+61% | $57.8M+32% |
| SG&A | $3.9M−31% | $4.5M−19% | $4.5M−34% | $4.4M+22% | $4.4M+13% | $4.5M−2% | $4.2M−5% | $4M−10% | $5.9M+35% | $6.9M+54% | $8.8M+106% | $9.4M+137% |
| −$23.3M+1% | −$30.4M+12% | −$34.3M+16% | −$33.5M+55% | −$37.6M+61% | −$36.8M+21% | −$34.9M+2% | −$47.9M+43% | −$45.9M+22% | −$50.1M+36% | −$58M+66% | −$67.2M+40% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$21.5M−5% | −$26.8M+2% | −$31M+10% | −$30.4M+51% | −$34.6M+61% | −$33.6M+25% | −$30.4M−2% | −$43.8M+44% | −$42.2M+22% | −$46.1M+37% | −$53.1M+75% | −$63.2M+44% |
| −$0.48−16% | −$0.49−25% | −$0.56−20% | −$0.54+10% | −$0.60+25% | −$0.45−8% | −$0.36−36% | −$0.51−6% | −$0.49−18% | −$0.50+11% | −$0.52+44% | −$0.61+20% | |
| 45M+12% | 54.9M+37% | 55.6M+38% | 56.3M+38% | 57.3M+27% | 75.3M+37% | 85.4M+54% | 85.5M+52% | 85.7M+50% | 91.3M+21% | 102.8M+20% | 104.5M+22% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Olema Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OLMAOlema Pharmaceuticals | $560.9M | n/m | n/a | n/m | n/m | n/m | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| Peer median | $679.7M | 12.8× | 13.6× | 1.5× | +10% | 11.6% |
Investors who own it
Investors we follow who held Olema Pharmaceuticals at the end of Jun 30, 2026, from their 13F filings.
- Stanley DruckenmillerDuquesne Family Office0.3% of portfolio
More on Olema Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .